REGN | Regeneron Pharmaceuticals

571.75 -3.73 (-0.65%)

REGN Price Profile

Open

$570.11

CLOSE

$571.75

DAY RANGE

566.77 - 577.81

52 WEEK RANGE

516.04 - 747.42

MARKET CAP

65.09B

Trading volume

199.22K

Prev. Close

575.48

50 Day MA

632.36

Shares Outstanding

105.72M

Public Float

99.54M

Average Volume

868.38K

Beta

0.17

PEG Ratio

0.67

Shares Shorted

1.64M

% OF SHARES SHORTED

1.83%

Short Ratio

2.17

1 Year Performance

17.00%

Diluted EPS (TTM)

62.53

Q Revenue Growth

0.51

Ebitda

7.47B

Gross Profit (TTM)

4.46B

Total Cash (MRQ)

5.79B

Total Debt (MRQ)

2.7B

  • MRQ = Most Recent Quarter.
  • TTM = Trailing Twelve Months.

Regeneron Pharmaceuticals (REGN) company profile

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products to treat severe medical conditions. Some of the firm’s products include EYLEA injection and ARCALYST injection. The company’s commercialized medicines are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and other rare diseases.

Latest REGN News

AD